Biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs — very small proteins — for treating diseases such as diabetes and cancer.
Biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs — very small proteins — for treating diseases such as diabetes and cancer.